Multidrug efflux pump subunit AcrB
Target name: Multidrug efflux pump subunit AcrB (Acridine resistance protein B)
Uniprot Accession: P31224
Origin: Escherichia coli (strain K12)
Class: Multidrug efflux pump
Sequence: Full-length, wildtype sequence, with a C-terminus, 6xHis-tag
Affinity Tag: His-tag (C-terminal)
Catalogue number: PP4
Theor. MW: 114.6 kDa
Shipment temperature: Dry Ice
Storage conditions: Store at -80°C
Expression system: Escherichia coli (BL21C43)
Purification: Immobilized Metal Affinity Chromatography
Activity: Confirmed by ligand binding
Concentration: Up to 5mg/ml
Sample buffer: 25mM Na2HPO4 100mM NaCl, 0.01% DDM (also available in optimized thermostable composition)
Available quantity: From 10µg up to mg scale
Multidrug efflux pump subunit AcrB: We employ a novel & custom-built method to give us an advantage
CALIXAR’s Acridine resistance protein B enables reliable fragment-based drug design (FBDD), structure-based drug discovery (SBDD) and antibody discovery against this specific target.
Unlike CALIXAR’s AcrB transporters, other alternative strategies result in an Acridine resistance protein B that becomes mutated and truncated.
As with all transporters, Acridine resistance protein B is a delicate targets, difficult to manufacture natively without particular know-how. Traditionally, Acridine resistance protein B was frequently developed in a solution that inherently cannot be pure, neither native(truncated, mutated), and consequently very unstable.
With CALIXAR’s expertise, we are capable of producing Multidrug efflux pump subunit AcrB that preserve the native structure and function of the target. Our AcrB transporter is pure, native, unaltered and stable. This is unparalleled on the market and at the vanguard of Membrane Protein technology.
See the application note related to the AcrB optimise thermostable composition: “A collaborative gene-to-structure workflow using cryoEM”
CALIXAR’S Acridine resistance protein B is unaltered, unmutated and untruncated targets that sustain their structural and functional integrity. This membrane protein transporter is purified and stabilized full length and wild-type (native), produced in a prokaryotic arrangement (E.coli).
Calixar’s Acridine resistance protein B is used for (bio)drug discovery and is adapted for application in Pharmaceutical, biotechnology companies, as well as for academic teams that are involved in the life science disciplines.
- Antibodies (including nanobodies, scaffold proteins, aptamers)
- Small molecules
- 3D Structures (classical X-ray or XFEL, Cryo-EM, NMR)
- Drug discovery (Screening: HTS, FBDD, SBDD; Hit and lead validation)
- Antibody discovery (Immunization and display technologies)
- Clinical stage (drug validation on reliable native AcrB)